RB1 and glioblastoma: 50% of glioblastoma patients have been found to harbour alterations in cyclin D1/CDK4/6-CDKN2A(p16INK4A)-Rb axis; hence, the use of CDK inhibitors in the treatment of glioblastoma warrants further investigation [7].